Woman sitting on park bench looking at her phone.

Sign Up

Say yep to staying
up to date

Actor portrayal

""
Being informed starts here

This is your ticket in—sign up to learn more about VYEPTI and how it works, get insurance info, study results, and more.

All fields are required unless marked optional.

Have you been prescribed VYEPTI?

If you're not prescribed VYEPTI yet, that's okay. You won't be enrolled in {VYEPTI GO}, but you can still fill out the form and a nurse will get in touch with you. You can also choose to call 833-4-VYEPTI, option 2 during live support hours instead.

SMS Terms and Conditions

By agreeing to these VYEPTI GO Support Program ("Program") text message Terms and Conditions, you agree to receive text messages on your mobile device subject to the Terms and Conditions described below. You also consent to receive autodialed and/or pre-recorded calls and/or text messages from or on behalf of VYEPTI at the telephone number provided above. You understand that this consent is not a condition of purchase or use of VYEPTI or of any Lundbeck product or service.

  • Message frequency will vary by use while enrolled in the Program
  • There is no fee payable to Lundbeck to receive text messages; however, your carrier’s message and data rates may apply
  • Data obtained from you in connection with your registration for, and use of, this SMS service may include your phone number and/or email address, related carrier information and will be used to administer this Program and to provide Program benefits such as information about your prescription, appointment reminders, as well as Program updates and alerts
  • Lundbeck will not be liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator
  • This Program is valid with most major US carriers, including: Verizon Wireless, Sprint, Nextel, Boost, T-Mobile®, AT&T, Alltel, ACS Wireless, Bluegrass Cellular, Carolina West Wireless, CellCom, Cellular One of East Central Illinois (ECIT), Cincinnati Bell, Cricket, C-Spire Wireless, Duet IP (AKA Max/Benton/Albany), Element Mobile, Epic Touch, GCI Communications, Golden State, Hawkeye (Chat Mobility), Hawkeye (NW Missouri Cellular), Illinois Valley Cellular (IVC), Inland Cellular, iWireless, Keystone Wireless (Immix/PC Management), MetroPCS, MobiPCS, Mosaic, MTPCS/Cellular One (Cellone Nation), Nex-Tech Wireless, nTelos, Panhandle Telecommunications, Pioneer, Plateau, Revol Wireless, Rina-Custer, Rina-All West, Rina-Cambridge Telecom Coop, Rina-Eagle Valley Comm, Rina-Farmers Mutual Telephone Co, Rina-Nucla Nutria Telephone Co, Rina-Silver Star, Rina-South Central Comm, Rina-Syringa, Rina-UBET, Rina-Manti, Simmetry, South Canaan/CellularOne of NEPA, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, West Central Wireless (includes Five Star Wireless)
  • Lundbeck may be required to contact the user if an adverse event is reported
  • Lundbeck reserves the right to rescind, revoke, or amend the VYEPTI GO Support Program without notice at any time
  • You can unsubscribe from the Program by texting STOP to 35865. For questions about this program, text HELP or contact the customer support center at 833-4-VYEPTI
  • Carriers are not liable for delayed or undelivered messages
  • Please review our Privacy Policy here

VYEPTI® logo.

Thank you for signing up to stay informed about migraine and VYEPTI. Look out for email communications from us soon.

IMPORTANT SAFETY INFORMATION
AND APPROVED USE

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

APPROVED USE

VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash; swelling of your face, lips, tongue, or throat; if you have trouble breathing; hives; or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information.

APPROVED USE

VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash; swelling of your face, lips, tongue, or throat; if you have trouble breathing; hives; or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information.